

Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Fleischmann R, Mysler E, Bessette L, *et al.* Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. *RMD Open* 2022;8:e002012. doi: 10.1136/rmdopen-2021-002012

Under the Efficacy heading, the sentence 'Numerically higher responses for patients who switched from adalimumab to upadacitinib vs those who switched from adalimumab to upadacitinib were also observed' has been changed to 'Numerically higher responses for patients who switched from adalimumab to upadacitinib vs those who switched from upadacitinib to adalimumab were also observed'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

RMD Open 2023;9:e002012corr1. doi:10.1136/rmdopen-2021-002012corr1

